title: Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
authors.forename: N
authors.initials: N
authors.lastname: Normanno
authors.forename: M
authors.initials: M
authors.lastname: Campiglio
authors.forename: F
authors.initials: F
authors.lastname: Perrone
authors.forename: A
authors.initials: A
authors.lastname: De Luca
authors.forename: S
authors.initials: S
authors.lastname: Menard
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D000077156:Gefitinib; D006801:Humans; D018579:Patient Selection; D011799:Quinazolines / Q000008:administration & dosage; D015203:Reproducibility of Results; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011799:Quinazolines; D000068878:Trastuzumab; D000077156:Gefitinib